



# WIPO Patent Information Services

William Meredith
April 2008






#### **Overview**

- WIPO's Patent Information Objectives
- PATENTSCOPE®
- Analysis Tools
- Future Plans



#### The context of Patent Information



- 1.6 Million new applications disclosed every year.
- An important resource of technical information.
- Increasing diversity of:
  - Countries of Origin
  - Countries of Filing
  - Languages
  - Users



#### WIPO's Patent Information Objectives

- Publication and Dissemination of PCT International Applications
- Electronic Publication via PATENTSCOPE®
- PCT Data Production dissemination of high-volume data to offices and subscribers

#### Enhanced Utilisation of Patent Information

- Seminars, workshops, etc
- Guides, tutorials
- Technology studies, patent landscapes, particularly on issues related to public policy
- Technical assistance projects with member states Integration of more data



## What is PATENTSCOPE®?

- WIPO's Patent Information Portal
- Database of 1.4 million international patent applications (PCT)
- Features:
  - Full text search
  - Status information
  - Graphical analysis tools
  - RSS notifications
  - Technology Focus



### PATENTSCOPE® Search



The invention provided herein relates to **vaccines** that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of **vaccine** compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions.

2. (069) (WO 2006/076410) 20.07.2006 C07K 14/00 PCT/US2006/000944 ANTIGEN EXPRESS, INC. HYBRID PEPTIDE VACCINES

Disclosed is an **antigen** presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian li-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: \_) and non-N-terminal deletion modifications thereof that retain **antigen** presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being...

3. (066) (WO 2001/042445) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS 14.06.2001 A61K 39/00

PCT/US2000/033293 THE GOVERNMENT
OF THE UNITED
STATES OF
AMERICA,
asrepresented by THE
DEPARTMENT OF
HEALTH AND
HUMAN SERVICES

Full text search in Description and/or Claims text

**Unlimited Keywords** 

Bibliographic search (classification, applicant, inventor, dates, etc)

Boolean operators (AND, OR, NOT), truncation, range searches




#### **Status Information**

- Patent rights are territorial (although disclosure is global)
- Patents may or may not be granted and may or may not remain valid and in force
- Patents are limited by the scope of their claims

Status information is critical to understanding what is patented and where



#### PATENTSCOPE® Documents



Published Documents and related file contents


Search reports (prior art)

Written opinions and preliminary examination reports (patentability)



#### PATENTSCOPE® National Phase Status

#### (WO/2002/092812) ARTIFICIAL HUMAN CHROMOSOME CONTAINING HUMAN ANTIBODY À LIGHT CHAIN GENE



2.6 Million notification from 30+ offices

Legal status (where available)
Internet hyperlinks to certain
offices (further status
information, translations, etc)



## PATENTSCOPE® Graphics

1. Enter any search criteria

2. Click on the Graphics icon

Refine Search (h5n1 or hpai) and (vaccine\* or antigen)

\_\_\_



Score Title Pub. Date Int. Class App. Num Applicant

1. (100) (WO 2007/092792) YEAST-BASED VACCINE FOR INDUCING AN IMMUNE RESPONSE 16.08.2007 A61K 39/145 PCT/US2007/061572 GLOBEIMMUNE, INC.

The invention provided herein relates to **vaccines** that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of **vaccine** compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions.

2. (055) (WO 2006/100111) COMPOSITION

28.09.2006 A61K 39/39 PCT/EP2006/002838 GLAXOSMITHKLINE BIOLOGICALS S.A.

The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against various diseases. In particular the invention relates to vaccine formulations comprising an oil-in-water emulsion adjuvant and 3D-MPL, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation, wherein the oil in water emulsion comprises a sterol, a metabolisable oil and an emulsifying agent.

3. (055) (WO 2007/053696) RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION


10.05.2007 A61K 48/00


PCT/US2006/042681 ALNYLAM PHARMACEUTICALS, INC.


The invention relates to compositions and methods for modulating the expression of influenza viral genes, and more particularly to the downregulation of influenza viral genes by chemically modified oligonucleotides




## PATENTSCOPE® Graphics












#### PATENTSCOPE® RSS Notifications





## **Demonstration**



#### **Some Caveats**

- Searching by simple keywords can lead to mis-interpretation. Beware of:
  - Ambiguity
  - Semantics
  - Obfuscation
- Search by classification (IPC) will improve the precision of a search
- Status information is always incomplete validate your results
- No single online database has fully extensive coverage



## PATENTSCOPE® - Work in Progress

- Integrate more patent data from more patent offices
- -(Technical co-operation projects in Latin America, Africa and Asia)
- Language tools
- Patent landscapes online



## **Thank You**